Patents by Inventor Christina Udesen

Christina Udesen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIVALENT ANTISENSE OLIGONUCLEOTIDES
    Publication number: 20180127754
    Abstract: The present invention provides bivalent molecules comprising a first oligonucleotide linked to a second oligonucleotide. The first and the second oligonucleotide are preferably linked via a linking moiety. Preferably, both the first and/or the second oligonucleotide comprise an antisense sequence complementary to a cellular RNA such as mRNA or microRNA.
    Type: Application
    Filed: November 10, 2017
    Publication date: May 10, 2018
    Inventors: Thorleif Moeller, Christina Udesen
  • Oligonucleotides for modulation of target RNA activity
    Patent number: 9290767
    Abstract: The present invention relates to oligonucleotides for modulation of target RNA activity. Thus, the invention provides oligonucleotides that bind to microRNA binding sites of target RNA. The oligonucleotides may activate RNase H or RNAi. In a preferred embodiment, the oligonucleotides prevents a micro RNA from binding to its binding site of the target RNA and thereby prevent the microRNA from regulating the target RNA. Such oligonucleotides have uses in research and development of new therapeutics.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: March 22, 2016
    Assignee: MIRRX THERAPEUTICS A/S
    Inventors: Thorleif Moeller, Christina Udesen
  • OLIGONUCLEOTIDES FOR MODULATION OF TARGET RNA ACTIVITY
    Publication number: 20150344892
    Abstract: The present invention relates to oligonucleotides for modulation of target RNA activity. Thus, the invention provides oligonucleotides that bind to microRNA binding sites of target RNA. The oligonucleotides may activate RNase H or RNAi. In a preferred embodiment, the oligonucleotides prevents a micro RNA from binding to its binding site of the target RNA and thereby prevent the microRNA from regulating the target RNA. Such oligonucleotides have uses in research and development of new therapeutics.
    Type: Application
    Filed: August 20, 2015
    Publication date: December 3, 2015
    Inventors: Thorleif MOELLER, Christina Udesen
  • Oligonucleotides for modulation of target RNA activity
    Patent number: 9145557
    Abstract: The present invention relates to oligonucleotides for modulation of target RNA activity. Thus, the invention provides oligonucleotides that bind to microRNA binding sites of target RNA. The oligonucleotides may activate RNase H or RNAi. In a preferred embodiment, the oligonucleotides prevents a micro RNA from binding to its binding site of the target RNA and thereby prevent the microRNA from regulating the target RNA. Such oligonucleotides have uses in research and development of new therapeutics.
    Type: Grant
    Filed: November 23, 2011
    Date of Patent: September 29, 2015
    Assignee: MIRRX THERAPEUTICS A/S
    Inventors: Thorleif Moeller, Christina Udesen
  • OLIGONUCLEOTIDES FOR MODULATION OF TARGET RNA ACTIVITY
    Publication number: 20140031537
    Abstract: The present invention relates to oligonucleotides for modulation of target RNA activity. Thus, the invention provides oligonucleotides that bind to microRNA binding sites of target RNA. The oligonucleotides may activate RNase H or RNAi. In a preferred embodiment, the oligonucleotides prevents a micro RNA from binding to its binding site of the target RNA and thereby prevent the microRNA from regulating the target RNA. Such oligonucleotides have uses in research and development of new therapeutics.
    Type: Application
    Filed: November 23, 2011
    Publication date: January 30, 2014
    Applicant: MIRRX THERAPEUTICS A/S
    Inventors: Thorleif Moeller, Christina Udesen
  • BIVALENT ANTISENSE OLIGONUCLEOTIDES
    Publication number: 20130079505
    Abstract: The present invention provides bivalent molecules comprising a first oligonucleotide linked to a second oligonucleotide. The first and the second oligonucleotide are preferably linked via a linking moiety. Preferably, both the first and/or the second oligonucleotide comprise an antisense sequence complementary to a cellular RNA such as mRNA or microRNA.
    Type: Application
    Filed: March 24, 2011
    Publication date: March 28, 2013
    Applicant: MIRRX THERAPEUTICS A/S
    Inventors: Thorleif Moeller, Christina Udesen